<p>Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - 獲取免費報告) 的股價在週三的午盤交易中下跌了 3.6%。該股最低交易價格為 15.00 美元，最後交易價格為 15.05 美元。午盤交易中成交了 157,665 股，較平均交易量 76,094 股增加了 107%。該股此前收盤價為 15.61 美元。</p>
<p>獲取 <strong>Coeptis Therapeutics</strong> 的提醒：</p>
<h2>分析師設定新目標價</h2>
<p>另外，Weiss Ratings 在 10 月 8 日的研究報告中重新發布了對 Coeptis Therapeutics 股票的 “賣出（e+）” 評級。一位研究分析師對該股給予了賣出評級，根據 MarketBeat 的數據，該股的共識評級為 “賣出”。</p>
<p><strong>查看我們關於 Coeptis Therapeutics 的最新研究報告</strong></p>
<h2>Coeptis Therapeutics 股票下跌 3.6%</h2>
<p>該股市值為 8037 萬美元，市盈率為-5.26，貝塔值為-0.53。該公司 50 日移動平均線為 15.78 美元，200 日移動平均線為 12.76 美元。公司的流動比率為 2.21，速動比率為 2.21，債務股本比率為 0.01。</p>
<p>Coeptis Therapeutics (NASDAQ:COEP - 獲取免費報告) 最近於 11 月 13 日發佈了季度財報。該公司報告本季度每股收益（EPS）為-0.58 美元。該公司本季度的收入為 24 萬美元。</p>
<h2>對 Coeptis Therapeutics 的對沖基金看法</h2>
<p>一家對沖基金最近在 Coeptis Therapeutics 股票中購買了新股份。Yorkville Advisors Global LP 在第三季度收購了 Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - 免費報告) 的新股份，根據該公司最近向證券交易委員會提交的 13F 文件，該公司收購了 8,000 股，價值約 14 萬美元。Coeptis Therapeutics 在 Yorkville Advisors Global LP 的投資組合中佔比約為 0.0%，是其第 24 大持倉。Yorkville Advisors Global LP 在最近一個季度末持有 Coeptis Therapeutics 的 0.17%。13.88% 的股票由機構投資者和對沖基金持有。</p>
<h2>Coeptis Therapeutics 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Coeptis Therapeutics Holdings, Inc.是一家生物製藥公司，開發針對癌症患者的細胞治療平台。其產品組合包括 CD38-GEAR-NK，一種用於治療與 CD38 相關的癌症的細胞治療，包括多發性骨髓瘤、慢性淋巴細胞白血病和急性髓性白血病；SNAP-CAR，一種與標記的腫瘤特異性抗體共同管理的 CAR T 細胞治療平台，可能針對不同類型的腫瘤，包括血液惡性腫瘤和實體瘤；以及 CD38-Diagnostic，一種體外篩查工具，用於分析癌症患者是否可能適合接受抗 CD38 單克隆抗體治療。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票而非 Coeptis Therapeutics</li>
<li>10 美元以下的最佳股票</li>
<li>市場動量：3 只有望大幅突破的股票</li>
<li>在經濟衰退中與這些分紅之王共度難關</li>
<li>Casey’s General Stores 將繼續上漲的 3 個理由</li>
<li>什麼是分紅挑戰者？</li>
<li>黃金交叉警報：3 只具有重大上漲潛力的股票</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Coeptis Therapeutics 嗎？</h2>
<p>在你考慮 Coeptis Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Coeptis Therapeutics 並不在名單上。</p>
<p>雖然 Coeptis Therapeutics 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

COEP

<p>Coeptis Therapeutics（納斯達克代碼：COEP）股價在午盤交易中下跌了 3.6%，交易量顯著增加。分析師已給予 “賣出” 評級，該公司的市值為 8037 萬美元。儘管最近對對沖基金的關注增加，Coeptis Therapeutics 並未成為分析師推薦的頂級股票之一</p>

<p>Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Get Free Report)'s share price fell 3.6% during mid-day trading on Wednesday . The stock traded as low as $15.00 and last traded at $15.05. 157,665 shares traded hands during mid-day trading, an increase of 107% from the average session volume of 76,094 shares. The stock had previously closed at $15.61.</p>
<div class="lb-trans"><p>Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - 獲取免費報告) 的股價在週三的午盤交易中下跌了 3.6%。該股最低交易價格為 15.00 美元，最後交易價格為 15.05 美元。午盤交易中成交了 157,665 股，較平均交易量 76,094 股增加了 107%。該股此前收盤價為 15.61 美元。</p>
</div><p>Get <strong>Coeptis Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Coeptis Therapeutics</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Separately, Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Coeptis Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日的研究報告中重新發布了對 Coeptis Therapeutics 股票的 “賣出（e+）” 評級。一位研究分析師對該股給予了賣出評級，根據 MarketBeat 的數據，該股的共識評級為 “賣出”。</p>
</div><p><strong>Check Out Our Latest Research Report on Coeptis Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Coeptis Therapeutics 的最新研究報告</strong></p>
</div><h2>Coeptis Therapeutics Stock Down 3.6%</h2>
<div class="lb-trans"><h2>Coeptis Therapeutics 股票下跌 3.6%</h2>
</div><p>The stock has a market capitalization of $80.37 million, a price-to-earnings ratio of -5.26 and a beta of -0.53. The firm has a 50-day moving average of $15.78 and a 200 day moving average of $12.76. The company has a current ratio of 2.21, a quick ratio of 2.21 and a debt-to-equity ratio of 0.01.</p>
<div class="lb-trans"><p>該股市值為 8037 萬美元，市盈率為-5.26，貝塔值為-0.53。該公司 50 日移動平均線為 15.78 美元，200 日移動平均線為 12.76 美元。公司的流動比率為 2.21，速動比率為 2.21，債務股本比率為 0.01。</p>
</div><p>Coeptis Therapeutics (NASDAQ:COEP - Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.58) earnings per share (EPS) for the quarter. The firm had revenue of $0.24 million for the quarter.</p>
<div class="lb-trans"><p>Coeptis Therapeutics (NASDAQ:COEP - 獲取免費報告) 最近於 11 月 13 日發佈了季度財報。該公司報告本季度每股收益（EPS）為-0.58 美元。該公司本季度的收入為 24 萬美元。</p>
</div><h2>Hedge Funds Weigh In On Coeptis Therapeutics</h2>
<div class="lb-trans"><h2>對 Coeptis Therapeutics 的對沖基金看法</h2>
</div><p>A hedge fund recently bought a new stake in Coeptis Therapeutics stock. Yorkville Advisors Global LP acquired a new stake in shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 8,000 shares of the company's stock, valued at approximately $140,000. Coeptis Therapeutics makes up about 0.0% of Yorkville Advisors Global LP's investment portfolio, making the stock its 24th biggest position. Yorkville Advisors Global LP owned 0.17% of Coeptis Therapeutics at the end of the most recent quarter. 13.88% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一家對沖基金最近在 Coeptis Therapeutics 股票中購買了新股份。Yorkville Advisors Global LP 在第三季度收購了 Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - 免費報告) 的新股份，根據該公司最近向證券交易委員會提交的 13F 文件，該公司收購了 8,000 股，價值約 14 萬美元。Coeptis Therapeutics 在 Yorkville Advisors Global LP 的投資組合中佔比約為 0.0%，是其第 24 大持倉。Yorkville Advisors Global LP 在最近一個季度末持有 Coeptis Therapeutics 的 0.17%。13.88% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Coeptis Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Coeptis Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.</p>
<div class="lb-trans"><p>Coeptis Therapeutics Holdings, Inc.是一家生物製藥公司，開發針對癌症患者的細胞治療平台。其產品組合包括 CD38-GEAR-NK，一種用於治療與 CD38 相關的癌症的細胞治療，包括多發性骨髓瘤、慢性淋巴細胞白血病和急性髓性白血病；SNAP-CAR，一種與標記的腫瘤特異性抗體共同管理的 CAR T 細胞治療平台，可能針對不同類型的腫瘤，包括血液惡性腫瘤和實體瘤；以及 CD38-Diagnostic，一種體外篩查工具，用於分析癌症患者是否可能適合接受抗 CD38 單克隆抗體治療。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Coeptis Therapeutics</li>
<li>Best Stocks Under $10.00</li>
<li>Market Momentum: 3 Stocks Poised for Major Breakouts</li>
<li>Ride Out The Recession With These Dividend Kings</li>
<li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li>
<li>What Are Dividend Challengers?</li>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票而非 Coeptis Therapeutics</li>
<li>10 美元以下的最佳股票</li>
<li>市場動量：3 只有望大幅突破的股票</li>
<li>在經濟衰退中與這些分紅之王共度難關</li>
<li>Casey’s General Stores 將繼續上漲的 3 個理由</li>
<li>什麼是分紅挑戰者？</li>
<li>黃金交叉警報：3 只具有重大上漲潛力的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Coeptis Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Coeptis Therapeutics 嗎？</h2>
</div><p>Before you consider Coeptis Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Coeptis Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coeptis Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Coeptis Therapeutics 並不在名單上。</p>
</div><p>While Coeptis Therapeutics currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Coeptis Therapeutics 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Coeptis Therapeutics（NASDAQ:COEP）股價下跌 3.6% - 現在是賣出的時候嗎？